Personalized medicine has changed considerably following rapid developments in the technology, both in terms of things that can be addressed by genetic and genomic information, as well as sophisticated methods that have been devised to be able to use this information, according to Edmund Pezalla, MD, MPH.
Particularly in oncology, Pezalla thinks drug development has been the primary driver for the use of personalized medicine—drugs that are targeted for specific markers expressed on particular tumor types. “That has been extremely helpful in getting patients the right therapies. The sophistication has vastly improved and that has definitely helped.”
The early phase of personalized medicine, he explained, was used to test drug metabolism and other things that did not yield improved patient outcomes or lead to better treatment decisions. Pezalla believes this scenario has now changed, both in oncology and other therapeutic areas such as, rheumatoid arthritis.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More